Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2003
12/24/2003CN1462804A Filtering out non essential segment in copying adenovirus of birds, and its gene engineering products
12/24/2003CA2489292A1 Vectors for expression of hml-2 polypeptides
12/24/2003CA2489224A1 Novel polynucleotides encoding lamprey gnrh-iii
12/24/2003CA2488896A1 Multifunctional polypeptides
12/24/2003CA2488858A1 Immunotoxin as a therapeutic agent and uses thereof
12/24/2003CA2488821A1 Methods and compositions for grafting functional loops into a protein
12/23/2003US6667295 DNA vaccine against feline immunodeficiency virus
12/23/2003US6667294 Freeze drying aqueous solution
12/23/2003US6667293 Of certain phosphorothioate antisense oligonucleotides used to treat pathogenic infections, cancer, and inherited conditions
12/23/2003US6667174 Expression vectors containing hybrid ubiquitin promoters
12/23/2003US6667157 Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus VPR protein
12/23/2003US6667152 Method for selective inactivation of viral replication
12/23/2003US6667034 Human gene therapy; culture product; adjustment of metabolism; regeneration bone marrow
12/23/2003CA2301575C Vectors and methods for immunization or therapeutic protocols
12/19/2003WO2002101076A2 Methods for targeted expression of therapeutic nucleic acid
12/19/2003CA2460095A1 Methods for targeted expression of therapeutic nucleic acid
12/18/2003WO2003104485A2 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003WO2003104470A2 Retrons for gene targeting
12/18/2003WO2003104468A1 A semliki forest virus based expression vector for the central nervous system
12/18/2003WO2003104467A1 Means and methods for the production of adenovirus vectors
12/18/2003WO2003104416A2 Spliceosome mediated rna trans-splicing in stem cells
12/18/2003WO2003104412A2 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
12/18/2003WO2003104402A2 Non-polymeric hematopoietic cell clots for delivery of active agents
12/18/2003WO2003104392A2 Improved reagents and methods for producing parvoviruses
12/18/2003WO2003104279A1 Regulation of a human g protein-coupled receptor
12/18/2003WO2003103725A1 Compositions and methods for the diagnosis and treatment of tumor
12/18/2003WO2003103721A1 Gene therapeutic for cerebrovascular disorders
12/18/2003WO2003103708A1 BIOFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION
12/18/2003WO2003103704A2 Proteins involved in the regulation of energy homeostasis
12/18/2003WO2003103701A1 Compositions and methods for treating diabetes
12/18/2003WO2003103605A2 Flexible vaccine assembly and vaccine delivery platform
12/18/2003WO2003103601A2 Methods of diagnosing & treating diabetes and insulin resistance
12/18/2003WO2003103586A2 Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
12/18/2003WO2003103581A2 Compositions and methods for liver growth and liver protection
12/18/2003WO2003093436A3 Treatment for phenylketonuria
12/18/2003WO2003082302A3 Bioadhesive directed somatic cell therapy
12/18/2003WO2003074692A3 Specific gene expression in colonic cancer cell lines
12/18/2003WO2003070271A3 Novel complexes for inducing an immune response
12/18/2003WO2003068930A3 Pseudomonas avr and hop proteins, their encoding nucleic acids, and use thereof
12/18/2003WO2003057849A3 Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats
12/18/2003WO2003057843A3 Methods and materials for modulating trpc4
12/18/2003WO2003057159A3 Psoriasin expression by breast epithelial cells
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003048298A3 Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
12/18/2003WO2003046179A3 G-protein coupled receptor lustr2 and uses thereof
12/18/2003WO2003040336A3 Stem and progenitor cell capture for tissue regeneration
12/18/2003WO2003040309A3 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
12/18/2003WO2003037164A3 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
12/18/2003WO2003029414A3 INTRODUCTION OF THE WLDs GENE FOR PREVENTION OF AXONAL DEGENERATION IN NEUROLOGICAL DISEASES
12/18/2003WO2003022040A9 Method for producing transgenic animals
12/18/2003WO2003016540A3 Humanised baculovirus
12/18/2003WO2003014342A3 Identification of a dna variant associated with adult type hypolactasia
12/18/2003WO2003012039A3 Targeting nucleic acids to a cellular nucleus
12/18/2003WO2003006045A3 Cxcl10 treatment of secondary tissue degeneration
12/18/2003WO2003002068A3 Diagnosis and treatment of cancer
12/18/2003WO2003000903A3 Regulation of human nek-like serine/threonine protein kinase
12/18/2003WO2002099035A3 Chimeric alphavirus replicon particles
12/18/2003WO2002092788A3 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
12/18/2003WO2002079388A3 Modulation of mhc class i antigen presentation
12/18/2003WO2002058724A3 Use of lp82 to treat body weight disorders
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
12/18/2003WO2002051980A9 In vitro-derived adult pluripotent stem cells and uses therefor
12/18/2003WO2002030257A9 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
12/18/2003WO2000040718A3 MUTANTS OF GNRPs AND VECTORS SUITABLE FOR THEIR EXPRESSION
12/18/2003US20030232777 An oligonucleotides or polynucleotides targeted to hybridization with the nucleic acids, gene expression inhibition, treating angiogenic diseases, metabolic disease, neurodegenerative disease, cancer, inflammation; gene therapy
12/18/2003US20030232775 Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression
12/18/2003US20030232769 Antisense modulation of G protein-coupled receptor 39 expression
12/18/2003US20030232767 Activating cancerous cells response to therapeutic agents, by administering cisplatin or oxaliplatin, applying ionizing radiation and hydrogen peroxide
12/18/2003US20030232443 Comprises oligonucleotides for controlling centromere protein B activities and expression; antisense therapy; gene expression inhibition; for treating cancer and autoimmune disorders
12/18/2003US20030232442 Comprises oligonucleotides for controlling translation initiation protein (PAZ/PIWI); antisense therapy; gene expression inhibition; for treating cancer and aberrant cellular differentiation disorders
12/18/2003US20030232437 Antisense modulation of VEGF-C expression
12/18/2003US20030232436 Comprises oligonucleotides for controlling endemic pemphigus foliaceus protein expression and activities; antisense therapy; gene expression inhibition; for treating skin and autoimmune disorders
12/18/2003US20030232435 Antisense modulation of amyloid beta protein precursor expression
12/18/2003US20030232434 Antisense modulation of PTPN12 expression
12/18/2003US20030232400 Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
12/18/2003US20030232074 For stimulating immune activation; for screening immunostimulatory compounds
12/18/2003US20030232058 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
12/18/2003US20030232037 Immunology, gene therapy
12/18/2003US20030232036 Alphavirus RNA replicon systems
12/18/2003US20030232035 Capable of expressing a heterologous sequence in target cells; vaccines
12/18/2003US20030232034 Antisense modulation of junctional adhesion molecule 3 expression
12/18/2003US20030232018 Stabilized formulations of adenovirus
12/18/2003CA2490357A1 Gene therapeutic for cerebrovascular disorders
12/18/2003CA2488328A1 Retrons for gene targeting
12/18/2003CA2488249A1 Spliceosome mediated rna trans-splicing in stem cells
12/18/2003CA2488246A1 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
12/18/2003CA2488227A1 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003CA2488059A1 Non-polymeric hematopoietic cell clots for delivery of active agents
12/18/2003CA2486584A1 Compositions and methods for treating diabetes
12/18/2003CA2486270A1 Vegfr modulating agents and methods for liver growth and liver protection
12/18/2003CA2486118A1 Flexible vaccine assembly and vaccine delivery platform
12/17/2003EP1371730A2 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
12/17/2003EP1371728A1 Gene encoding adseverin
12/17/2003EP1371723A1 Process for preparing an adenovirus-containing preparation
12/17/2003EP1371660A1 Vaccine
12/17/2003EP1371377A1 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
12/17/2003EP1370693A2 Amplified cancer gene wip1
12/17/2003EP1370685A2 Diagnosis of diseases associated with dna repair
12/17/2003EP1370684A2 Polynucleotides related to colon cancer
12/17/2003EP1370678A2 Methods and reagents for regulating apoptosis
1 ... 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 ... 870